> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Diamantas Touts FDA Moves to Boost U.S. Jobs
- URL: https://www.fdaweb.com/diamantas-touts-fda-moves-to-boost-u-s-jobs/
- Published: 2026-07-22T12:00:00.000Z
- Updated: 2026-09-14T13:43:26.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5161500

FDA acting commissioner **Kyle Diamantas** says the agency has been taking steps that will boost American jobs while protecting the supply of medicines. Writing in a 7/22 *Fox News* opinion piece, Diamantas [cites](ww.foxnews.com/opinion/fda-moves-boosting-american-jobs-protecting-medicine-supply.print) the PreCheck Pilot Program and new draft regulations to streamline pathways for distributed manufacturing and provide greater transparency about foreign medicine suppliers, as well as reimagining incentives within FDA’s control.

According to Diamantas, the PreCheck Pilot “is already unleashing a historic wave of domestic job creation, proving we can secure our health care while building a powerhouse economy.”

In the program’s first phase, he says, participating manufacturers receive technical and regulatory feedback before operations begin, preventing costly compliance mistakes. In the application submission phase, there reportedly is enhanced agency engagement to quickly resolve manufacturing questions, expedite the review of facility information, and fast-track inspections.

Diamantas claims that the first seven pilot participants “will anchor thousands of long-term, high-wage careers for American scientists, engineers, technicians, and operators, while instantly fueling thousands of jobs across the heartland. These are the kinds of stable, family-sustaining careers that anchor communities for generations, helping revitalize local economies and ensuring our brightest minds and hardest workers can build prosperous careers right in their home neighborhoods.”

Diamantas says the agency is now prioritizing applications for older, generic medicines that use domestic supply chains. “These lower-cost medicines make up roughly 90% of all prescriptions written in the U.S.,” he says, “yet they are the very drugs most frequently manufactured overseas. Moving production back home means bringing thousands more stable jobs to American factories.”

The essay concludes that through the PreCheck program, aggressive regulatory reform, and domestic prioritization, “FDA is acting as a collaborative catalyst for domestic growth. We are protecting patients, fueling a high-tech economic renaissance, and restoring American independence by putting American workers first.”